瘤中的基因组水平选择作为对治疗耐药性的普遍标志物
Erez Persi1, Praneeth R Sudalagunta2, Yuri I Wolf3
1Computational Biology Branch, Division of Intramural Research, National Library of Medicine, National Institutes of Health, Bethesda, MD, USA. erezpersi@gmail.com.
瘤进化受到自然进展和癌症治疗的影响. 抗治疗瘤转向中性演变,表明预后较差,并建议监测选择方案可以帮助临床决策.
科学领域:
- 在瘤学瘤学.
- 进化生物学 进化生物学
- 基因组学就是基因组学.
背景情况:
- 瘤进化是由生理因素和癌症疗法的选择性压力驱动的.
- 由于瘤内异质性,区分这些压力及其影响是具有挑战性的.
研究的目的:
- 区分生理和治疗选择性压力对瘤演变的影响.
- 为了研究瘤进化,治疗耐药性和患者预后之间的关系.
主要方法:
- 来自治疗和未治疗癌症患者的不同队列的基因组数据的分析.
- 对不同癌症类型和进展阶段的选择强度进行比较分析.
- 验证公布和原始数据集的发现.
主要成果:
- 在初级瘤进展期间,瘤基因组的选择强度在很大程度上是稳定的,在转移中具有癌症特异性特征.
- 在耐治疗瘤中观察到接近普遍的转向中性进化.
- 耐药瘤中性进化显着与患者预后的恶化有关.
结论:
- 在癌症治疗期间监测进化选择模式可以提供宝贵的见解.
- 这种监测可能有助于临床决策,以改善患者的治疗结果.
- 了解进化动态对于有效的癌症治疗至关重要.
更多相关视频
08:52Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
09:33Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor
Published on: August 25, 2023
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Treatment Resistant Cancers
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Treatment Resistent Cancers
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
